These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 33230039)
21. [Current trends in diagnosis and treatment of giant cell arteritis]. Czihal M; Lottspeich C; Hoffmann U Dtsch Med Wochenschr; 2018 Apr; 143(7):446-450. PubMed ID: 29614532 [TBL] [Abstract][Full Text] [Related]
22. Updates in the Management of Giant Cell Arteritis. Baig A; Gafoor-Haseeb S; Goldsher J; Siddique F Curr Neurol Neurosci Rep; 2024 Aug; 24(8):285-291. PubMed ID: 38913278 [TBL] [Abstract][Full Text] [Related]
23. Recent advances in the diagnosis and management of giant cell arteritis. Serling-Boyd N; Stone JH Curr Opin Rheumatol; 2020 May; 32(3):201-207. PubMed ID: 32168069 [TBL] [Abstract][Full Text] [Related]
24. Updates in the Diagnosis and Management of Giant Cell Arteritis. Uppal S; Hadi M; Chhaya S Curr Neurol Neurosci Rep; 2019 Aug; 19(9):68. PubMed ID: 31396718 [TBL] [Abstract][Full Text] [Related]
25. Tocilizumab for giant cell arteritis: an amazing result. Işık M; Kılıç L; Doğan İ; Calgüneri M Rheumatol Int; 2013 Nov; 33(11):2961-2. PubMed ID: 22965672 [TBL] [Abstract][Full Text] [Related]
26. Need and value of targeted immunosuppressive therapy in giant cell arteritis. Sandovici M; van der Geest N; van Sleen Y; Brouwer E RMD Open; 2022 Feb; 8(1):. PubMed ID: 35149602 [TBL] [Abstract][Full Text] [Related]
28. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Prieto-Peña D; Atienza-Mateo B; Patiño E; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Loricera J; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R Clin Exp Rheumatol; 2020; 38 Suppl 124(2):112-119. PubMed ID: 32441643 [TBL] [Abstract][Full Text] [Related]
29. Giant cell arteritis. Ninan J; Lester S; Hill C Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):169-88. PubMed ID: 27421223 [TBL] [Abstract][Full Text] [Related]
30. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411 [TBL] [Abstract][Full Text] [Related]
31. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients]. Broner J; Arnaud E Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884 [TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Chandran A; Udayakumar PD; Kermani TA; Warrington KJ; Crowson CS; Matteson EL Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-98-102. PubMed ID: 26016757 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic approach to giant cell arteritis. Masson C Joint Bone Spine; 2012 May; 79(3):219-27. PubMed ID: 22119350 [TBL] [Abstract][Full Text] [Related]
35. The Treatment of Giant Cell Arteritis in Different Clinical Settings. Pfeil A; Oelzner P; Hellmann P Front Immunol; 2018; 9():3129. PubMed ID: 30733723 [TBL] [Abstract][Full Text] [Related]
36. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091 [TBL] [Abstract][Full Text] [Related]